

## Eritrea Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Eritrea					
<b>2. Grant number:</b> 1821-ERI-12d-X; 15-ERI-08c-Y; 17-ERI-25a-Y					
<b>3. Date of Decision Letter:</b> 6 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2015 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2015-2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	US\$4,729,889 <sup>3</sup>	US\$1,031,500	US\$1,092,000	US\$1,117,000	US\$7,970,389
<b>10. Vaccine introduction grant (in US\$):</b> US\$100,000 disbursed on 28 April 2015					
<b>11. Product switch grant (in US\$):</b> US\$31,840.50 disbursed on 21 February 2017					
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
Type of supplies to be purchased with Gavi funds in each year	2015-2018		2019		
Number of Pneumococcal vaccines doses			306,400		
Annual Amounts (US\$)	US\$4,729,889 <sup>5</sup>		US\$1,031,500		
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
<b>14. Self-procurement:</b> N/A					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p><b>15. Co-financing obligations:</b> Reference code: 1821-ERI-12d-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>									
Type of supplies to be purchased with Country funds in each year	2019	2020	2021						
Number of vaccine doses	22,200	26,400	27,000						
Value of vaccine doses (US\$)	US\$64,924	US\$77,411	US\$79,189						
Total co-financing payments (US\$) (including freight)	US\$66,000	US\$78,500	US\$80,500						
<p><b>16. Operational support for campaigns:</b> Not applicable</p>									
<p><b>17. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>					Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
	Due dates								
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
<p><b>18. Financial clarifications:</b> N/A</p>									
<p><b>19. Other conditions:</b> N/A</p>									

Signed by,



**On behalf of Gavi**  
 Hind Khatib-Othman  
 Managing Director, Country Programmes  
 6 March 2019